ZA200208369B - Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate. - Google Patents
Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate. Download PDFInfo
- Publication number
- ZA200208369B ZA200208369B ZA200208369A ZA200208369A ZA200208369B ZA 200208369 B ZA200208369 B ZA 200208369B ZA 200208369 A ZA200208369 A ZA 200208369A ZA 200208369 A ZA200208369 A ZA 200208369A ZA 200208369 B ZA200208369 B ZA 200208369B
- Authority
- ZA
- South Africa
- Prior art keywords
- daily dosage
- conjugated estrogens
- medroxyprogesterone acetate
- menopausal
- estrogens
- Prior art date
Links
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 title claims description 105
- 229960002985 medroxyprogesterone acetate Drugs 0.000 title claims description 102
- 229940035811 conjugated estrogen Drugs 0.000 title claims description 77
- 238000002657 hormone replacement therapy Methods 0.000 title claims description 18
- 229940011871 estrogen Drugs 0.000 claims description 49
- 239000000262 estrogen Substances 0.000 claims description 49
- 238000011282 treatment Methods 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 30
- 230000002401 inhibitory effect Effects 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 18
- 230000001457 vasomotor Effects 0.000 claims description 18
- 210000000988 bone and bone Anatomy 0.000 claims description 17
- 206010060800 Hot flush Diseases 0.000 claims description 15
- 206010003694 Atrophy Diseases 0.000 claims description 13
- 241000283073 Equus caballus Species 0.000 claims description 13
- 230000037444 atrophy Effects 0.000 claims description 13
- 208000001132 Osteoporosis Diseases 0.000 claims description 11
- 201000000736 Amenorrhea Diseases 0.000 claims description 10
- 206010001928 Amenorrhoea Diseases 0.000 claims description 10
- 231100000540 amenorrhea Toxicity 0.000 claims description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000004483 Dyspareunia Diseases 0.000 claims description 6
- 208000003251 Pruritus Diseases 0.000 claims description 6
- 230000018109 developmental process Effects 0.000 claims description 6
- 150000003254 radicals Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010027514 Metrorrhagia Diseases 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 238000005115 demineralization Methods 0.000 claims description 5
- 230000002328 demineralizing effect Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims description 4
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims description 4
- 208000004746 Atrophic Vaginitis Diseases 0.000 claims description 4
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000020084 Bone disease Diseases 0.000 claims description 4
- 206010006298 Breast pain Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 206010014561 Emphysema Diseases 0.000 claims description 4
- 206010019799 Hepatitis viral Diseases 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 208000006662 Mastodynia Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000001738 Nervous System Trauma Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- 206010047163 Vasospasm Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 229940038500 a synthetic conjugated estrogen Drugs 0.000 claims description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 230000003679 aging effect Effects 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 206010013990 dysuria Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000027939 micturition Effects 0.000 claims description 4
- 230000004112 neuroprotection Effects 0.000 claims description 4
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 claims description 4
- 230000010410 reperfusion Effects 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 201000008827 tuberculosis Diseases 0.000 claims description 4
- 208000019206 urinary tract infection Diseases 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 230000003966 vascular damage Effects 0.000 claims description 4
- 201000001862 viral hepatitis Diseases 0.000 claims description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 3
- 206010038687 Respiratory distress Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 230000019771 cognition Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000000979 retarding effect Effects 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 230000009429 distress Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 47
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 46
- 229940063238 premarin Drugs 0.000 description 44
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 42
- 230000002354 daily effect Effects 0.000 description 29
- 229960005309 estradiol Drugs 0.000 description 24
- 229930182833 estradiol Natural products 0.000 description 23
- 239000000902 placebo Substances 0.000 description 17
- 229940068196 placebo Drugs 0.000 description 17
- 239000003826 tablet Substances 0.000 description 13
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 10
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 10
- 238000009164 estrogen replacement therapy Methods 0.000 description 10
- 239000000583 progesterone congener Substances 0.000 description 10
- 201000006828 endometrial hyperplasia Diseases 0.000 description 9
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000009245 menopause Effects 0.000 description 7
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 229960001652 norethindrone acetate Drugs 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 229940062399 cenestin Drugs 0.000 description 5
- 229960004766 estradiol valerate Drugs 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 229940053934 norethindrone Drugs 0.000 description 4
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229960003399 estrone Drugs 0.000 description 3
- HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 2
- NLLMJANWPUQQTA-UBDQQSCGSA-N 7,8-didehydro-17beta-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4C3=CCC2=C1 NLLMJANWPUQQTA-UBDQQSCGSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 2
- MPSOHXLZDRQABN-KOAPPJMKSA-N [(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8r,9s,13s,14s,16r,17 Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 MPSOHXLZDRQABN-KOAPPJMKSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003293 cardioprotective effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940108922 climara Drugs 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- PDRGHUMCVRDZLQ-UHFFFAOYSA-N d-equilenin Natural products OC1=CC=C2C(CCC3(C4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 2
- 229960003839 dienestrol Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 2
- 229960004913 dydrogesterone Drugs 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229940064258 estrace Drugs 0.000 description 2
- 229940074117 estraderm Drugs 0.000 description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
- VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 2
- 229950008385 estrone sulphate Drugs 0.000 description 2
- 229940081345 estropipate Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000002436 femur neck Anatomy 0.000 description 2
- -1 for example Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229940099990 ogen Drugs 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960000747 sodium estrone sulfate Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 229940044959 vaginal cream Drugs 0.000 description 2
- 239000000522 vaginal cream Substances 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- WFHDOIKSUKQTLH-IBXXTFBESA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 WFHDOIKSUKQTLH-IBXXTFBESA-N 0.000 description 1
- RVXHNBHNODFRPZ-JBOOOYMWSA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RVXHNBHNODFRPZ-JBOOOYMWSA-N 0.000 description 1
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 1
- SONVSJYKHAWLHA-UHFFFAOYSA-N 3-hydroxy-13-methyl-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound OC1=CC=C2C3=CCC(C)(C(CC4)=O)C4C3CCC2=C1 SONVSJYKHAWLHA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- OZPWNCNLFBVVEN-RFYLDXRNSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(9s,13s,14s)-13-methyl-17-oxo-9,11,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;[(8r,9 Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1.OS(=O)(=O)OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 OZPWNCNLFBVVEN-RFYLDXRNSA-N 0.000 description 1
- NAUDKYVGHCCLOT-LAQCMFAESA-N [(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 NAUDKYVGHCCLOT-LAQCMFAESA-N 0.000 description 1
- YJBYRYVLFAUXBJ-HFTRVMKXSA-N [(9s,13s,14s)-13-methyl-17-oxo-9,11,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 YJBYRYVLFAUXBJ-HFTRVMKXSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940060585 alora Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001441 androstanes Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- PDRGHUMCVRDZLQ-WMZOPIPTSA-N equilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-WMZOPIPTSA-N 0.000 description 1
- 229940083543 estradiol 1 mg Drugs 0.000 description 1
- 229940083544 estradiol 2 mg Drugs 0.000 description 1
- 229940098618 estring Drugs 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229940106582 estrogenic substances Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940085363 evista Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 208000028755 loss of height Diseases 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940018324 medroxyprogesterone acetate 10 mg Drugs 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003128 pregnanes Chemical class 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940053743 vivelle Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Description
or A a * ‘ HORMONE REPLACEMENT THERAPY
This invention relates to methods and pharmaceutical compositions for providing hormone replacement therapy in perimenopausal, menopausal, and postmenopausal women through the continuous administration of combinations of conjugated estrogens and medroxyprogesterone acetate. : :
Menopause is generally defined as the last natural menstrual period and is characterized by the cessation of ovarian function, leading to the substantial diminution of circulating estrogen in the bloodstream. Menopause is usually identified, in retrospect, after 12 months of amenorrhea. It is not a sudden event, but is often preceded by a time of irregular menstrual cycles prior to eventual cessation of menses. Following the cessation of menstruation, the decline in endogenous estrogen concentrations is typically rapid. There is a decrease in serum estrogens from circulating levels ranging from 40-250 pg/mL of estradiol and 40-170 pg/mL of : estrone during ovulatory cycles to less than 15 pg/mL of estradiol and 30 pg/mL of estrone in postmenopausal women.
As these estrogens decline during the time preceding (perimenopause) and following the menopause (postmenopause), various physiological changes may result, including vulvar and vaginal atrophy causing vaginal dryness, pruritus and dyspareunia, and vasomotor instability manifested as hot flushes. Other menopausal disturbances may include depression, insomnia, and nervousness. The long-term physiologic effects of postmenopausal estrogen deprivation may result in significant morbidity and mortality due to increase in the risk factors for cardiovascular disease ; and osteoporosis. Menopausal changes in blood lipid levels, a major component of the pathogenesis of coronary heart disease (CHD), may be precursors to increased incidence of ischemic heart disease, atherosclerosis, and other cardiovascular disease.
A rapid decrease in bone mass of both cortical (spine) and trabecular (hip) bone can
" Ws . be seen immediately after the menopause, with a total bone mass loss of 1% to 5% per year, continuing for 10 to 15 years.
Estrogen replacement therapy (ERT) is beneficial for symptomatic relief of 5 hot flushes and genital atrophy and for prevention of postmenopausal osteoporosis.
ERT has been recognized as an advantageous treatment for relief of vasomotor symptoms. There is no acceptable alternative to estrogen treatment for the atrophic changes in the vagina; estrogen therapy increases the vaginal mucosa and decreases vaginal dryness. Long term ERT is the key to preventing osteoporosis because it decreases bone loss, reduces spine and hip fracture, and prevents loss of height. In addition, ERT has been shown to be effective in increasing high density lipoprotein- cholesterol (HDL-C) and in reducing low density lipoprotein cholesterol (LDL-C), affording possible protection against CHD. ERT also can provide antioxidant protection against free radical mediated disorders or disease states. Estrogens have also been reported to confer neuroprotection, and inhibit neurodegenerative disorders, such as Alzheimer's disease (see U.S. Patent 5,554,601, which is hereby incorporated by reference). The following table contains a list of estrogen preparations currently : available. : 20 Estrogen replacement therapies available in the United States and/or Europe
Oral estrogens
Conjugated equine estrogens (natural) Premarin 0.3, 0.625,09, 1.25, 2.5 mg
Esterified estrogens (75-80% estrone sulfate Estratab 0.3,0.625,1.25,25 mg 6-15% equilin sulfate derived from plant sterols)
Estropipate (Piperazine estrone sulfate) Ogen Ortho-Est 0.625, 1.25,2.5 mg
Micronized estradiol Estrace 035, 1.0,2.0 mg
Raloxifene (selective estrogen receptor modulator) ~~ Evista 60 mg
Esterified estrogens and methylestosterone Estratest 1.25 mg esterified estrogen and 2.5 mg methylestosterone
Estratest HS 0.625 mg esterified estrogen and ! 1.25 mg methylestosterone
EE ny ; Estrogen replacement therapies available in the United States and/or Europe (Continued) i" Generic Name Brand Name Strength
Oral estrogens
Estradiol valerate Climaval 1 mg, 2 mg
Estradiol Elleste Solo 1 mg, 2 mg ]
Estradiol Estrofem 2 mg
Estradiol Estrofern Forte 4 mg
Piperazine esterone sulfate Harmogen 1.5 mg
Combination: Estrone Hormonin 14mg
Estradiol 0.6 mg
Estriol 0.27 mg
Estradiol valerate Progynova 1 mg, 2 mg
Estradiol Zumenon 1 mg, 2mg
Transdermal estrogens ) Estradiol Alora (twice weekly) 0.025, 0.0375, 0.05, 0.075,
Climara (weekly) 0.1 mg of estradiol released
Estraderm (2x weekly) daily (dose options for various oo
AE EE DE co ’ " Fem Patch (weekly) products) _ Vivelle (twice weekly)
Estradiol Dermestril 25, 50, 100 pug : : Estradiol Estraderm 25, 50, 100 ug : Estradiol Evorel (Systen) 25, 50, 75, 100 pg . Estradiol Fematrix 40, 80 ug :
Estradiol Menorest 25,37.5,50,75 ug : Progynova TS
Estradiol And TS Forte 50, 100 pg (Climara)
Vaginal estrogens . }
Conjugated equine estrogens Premarin vaginal
Dienestrol cream 0.625 mg/g
Estradiol Ortho dienestrol cream 0.1 mg/g
Estropipate Estring 7.5 ug . | Micronized estradiol Ogen vaginal cream 1.5 mg/g
Estrace vaginal cream 1.0 mg/g
To minimize the occurrence of estrogen-related side effects and to maximize the benefit-risk ratio, the lowest dose effective in relief of symptoms and prevention of osteoporosis should be used. Although ERT reduces the relative risk (RR) for ischemic heart disease (RR, 0.50) and osteoporosis (RR, 0.40), the relative risk of endometrial cancer for postmenopausal women with a uterus may be increased. ’ 10 There are extensive clinical data showing that the relative risk of endometrial cancer can be reduced by the addition of a progestin, either sequentially or continuously.
The addition of a progestin to estrogen therapy prevents estrogen-induced endometrial proliferation. Continuous combined hormone replacement therapy (HRT), with appropriate doses of daily estrogen and progestin, has been shown to be effective in relieving vaginal atrophy and vasomotor symptoms, preventing postmenopausal
Kd in . osteoporosis, and reducing the risk of endometrial cancer by prevention of endometrial hyperplasia. The following table contains a list of some currently available oral combination HRT products.
Oral Combination HRT Products
Brand Name Estrogen/Progestin Strengths
Activelle Estradiol 1 mg
Norethisterone acetate (NETA) 0.5 mg
Climagest Estradiol valerate (Climaval) lor2mg
Norethisterone (NET) 1 mg days 17-28
Cyclo Progynova Estradiol valerate 1 or 2 mg, days 1-21
Levonorgestrel 250 or 500 pg, days 2-21
Elleste Duet Estradiol lor2mg
Norethisterone acetate 1 mg days 17-28
Femoston Estradiol lor2mg
Dydrogesterone 10 or 20 mg
Kliogest Estradiol 2 mg
Norethisterone acetate 1 mg
Improvera Piperazine estrone sulfate 1.5 mg
Medroxyprogesterone acetate 10 mg, days 17-28 (MPA)
Nuvelle Estradiol valerate (Progynova) 2 mg
Levonorgestrel 75 ug, days 17-28
Premphase Conjugated estrogens 0.625 mg
MPA 5.0mg
Prempro Conjugated estrogens 0.625 mg
MPA 2.50r5.0mg
Trisequens Estradiol 2 or 4 mg, days 1-22
And Norethisterone 1 mg, days 23-28
Trisequens Forte 1 mg, days 13-22
Ortho-Prefest Estradiol 1.0 mg, days 1-6
Nogestimate 0.09 mg, days 4-6 ) Fembhrt 1/5 Ethiny] estradiol 1.0 mg
Norethindrone acetate 5 ug
Since it is possible that progestins ameliorate of the favorable estrogen effects on lipids and may potentially impair of glucose tolerance, it is desirable, and an objective to find the lowest dose estrogen plus progestin HRT product, which also
. minimizes or eliminates endometrial hyperplasia. In addition, a major factor affecting a woman's decision to start and to continue taking HRT is vaginal bleeding, and many o women would prefer a bleed-free product. Therefore, another objective is to provide the lowest effective dose which provides an acceptable bleeding pattem. Doses as low as NETA 0.5 mg, NET 0.35 mg, medroxyprogesterone acetate (MPA) 2.5 mg, levonorgesterel 0.25 mg, and dydrogesterone 5S mg have been used previously in continuous uninterrupted HRT regimens.
Thus, according to the present invention there is provided a pharmaceutical pack comprising daily dosage units comprising a combination of conjugated estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate, and further provided is the use of conjugated estrogens and medroxyprogesterone acetate in the manufacture of such pharmaceutical packs for the treatment or inhibition of menopausal or postmenopausal disorders in a perimenopausal, menopausal, or postmenopausal woman in need thereof.
FIG. 1 shows the mean number of hot flushes per day in patients receiving
PREMARIN plus MPA combinations or placebo.
FIG. 2 shows the mean severity of hot flushes in patients receiving
PREMARIN plus MPA combinations or placebo.
FIG. 3 shows the percentage of patients with amenorrhea in patients receiving
PREMARIN plus MPA combinations or placebo.
The purpose of this invention is to provide the significant benefits of a commercially successful HRT product, such as PREMPRO (0.625 mg conjugated equine estrogens, USP plus 2.5 mg MPA), while lowering the dosage of MPA below . that which has previously been demonstrated to be effective, and preferably also lowering the dosage of the conjugated estrogens. This invention provides a method of : 30 treating or inhibiting menopausal or postmenopausal disorders in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises providing to said woman, continuously and uninterruptedly over the treatment period, a combination of conjugated estrogens (natural or synthetic) and a daily dosage of
» o . about 1.5 mg MPA. The dosage is preferably provided as a pharmaceutical composition for use in treating menopausal or postmenopausal disorders which “ comprises a combination of conjugated estrogens and a dosage of about 1.5 mg MPA.
This invention further provides a pharmaceutical pack containing the daily dosage units of conjugated estrogen and MPA for continuous daily administration.
Conjugated estrogens refer to estrogenic steroidal substances in which one or : more functional groups (typically hydroxyl groups) on the steroid exists as a conjugate (typically a sulfate or glucuronide). The conjugated estrogens may be a single conjugated estrogen, or may consist of mixtures of various conjugated estrogens. Numerous conjugated estrogens are described in the literature or are : commercially available that are capable of being formulated for use in this invention either as a unitary estrogen, or may be mixed together with other synthetic and/or natural estrogens. oo
Conjugated estrogens may also contain other steroidal or non-steroidal compounds, which may, or may not, contribute to the overall biological effect. Such compounds include, but are not limited to, unconjugated estrogens, androstanes, and pregnanes. Preferred conjugated estrogens for use in this invention are PREMARIN (conjugated equine estrogens, USP) and CENESTIN (synthetic conjugated estrogens,
A).
PREMARIN (conjugated estrogens tablets, USP) for oral administration contains a mixture of estrogens obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares’ urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate, and at least the following 8 concomitant components, also as sodium sulfate conjugates: 17a-dihydroequilin, 17a-estradiol,
A8.,9-dehydroestrone, 17B-dihydroequilin, 17B-estradiol, equilenin, ; 17a-dihydroequilenin, and 17f3-dihydroequilenin. The make up of PREMARIN of
PREMARIN is currently being analyzed, and other components are in the process of ; being identified and characterized. PREMARIN is indicated in the treatment of moderate to severe vasomotor symptoms associated with the menopause; treatment of vulvar and vaginal atrophy; and prevention of osteoporosis, as well as other indications approved for estrogen products.
. CENESTIN (synthetic conjugated estrogens, A) tablets for oral administration contain a blend of 9 synthetic estrogenic substances: sodium estrone sulfate, sodium i” 17a-dihydroequilin sulfate, sodium 17a-estradiol sulfate, sodium equilenin sulfate, sodium 17o-dihydroequilenin sulfate, sodium equilin sulfate, sodium 17B- dihydroequilin sulfate, sodium 17f-estradiol sulfate, sodium 17a-dihydroequilenin sulfate. CENESTIN is indicated in the treatment of moderate to severe vasomotor symptoms associated with the menopause.
PREMARIN, CENESTIN, and medroxyprogesterone acetate are all available from commercial sources (Wyeth-Ayerst - PREMARIN and medroxyprogesterone acetate; Duramed - CENESTIN). The dosage of MPA is about 1.5 mg per day. Itis preferred that the conjugated estrogen constituent is PREMARIN. It is preferred that the dosage of PREMARIN is about 0.625 mg per day or less, and is more preferred that the dosage of PREMARIN is either about 0.45 mg per day or about 0.30 mg per day.
As used in accordance with this invention, the term "menopausal or postmenopausal disorder" refers to conditions, disorders, or disease states that are at least partially caused by the decreased estrogen production occurring during the perimenopausal, menopausal, or post-menopausal stages of a woman's life. Such disorders typically include, but are not limited to, one or more of : eo vasomotor instability, vasomotor symptoms such as hot flushes; e bone demineralization causing reduced bone mineral density, increased risk of developing osteoporosis; e vaginal or vulvar atrophy; atrophic vaginitis; vaginal dryness; pruritus; dyspareunia; dysuria; ee frequent urination; urinary incontinence; urinary tract infections, e raised cholesterol, triglycerides, Lp(a), or LDL levels; hypercholesteremia; hyperlipidemia; © e cardiovascular disease; atherosclerosis; peripheral vascular disease; restenosis, vasospasm; vascular wall damage from cellular events leading toward immune ; 30 mediated vascular damage; e free radical involvement in the development of cancers, central nervous system disorders, Alzheimer's disease, bone disease, aging, inflammatory disorders, peripheral vascular disease, rheumatoid arthritis, autoimmune diseases, respiratory distress, emphysema, prevention of reperfusion injury, viral hepatitis, chronic
E active hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral sclerosis, aging effects, adult respiratory distress syndrome, “ central nervous system trauma and stroke, or injury during reperfusion procedures; e dementias, neurodegenerative disorders, and Alzheimer's disease.
As used herein, menopausal also includes conditions of decreased estrogen production that may be surgically, chemically, or be caused by a disease state which leads to premature diminution or cessation of ovarian function.
The term "daily" means that the dosage is to be administered at least once a day. The frequency of administration is preferred to be once a day, but may be more than once a day, provided that any specified daily dosage is not exceeded.
The term "combination" of conjugated estrogens and MPA means that the daily dosage of each of the components of the combination is administered during the : treatment day. The components of the combination are preferably administered at the same time; either as a unitary dosage form containing both components, or as separate dosage units; the components of the combination can be administered at different times during the day, provided that the desired daily dosage is achieved.
The term "continuous and uninterrupted” means that there is no break in the treatment regimen, during the treatment period. Thus, “continuous, uninterrupted administration” of a combination, means that the combination is administered at least once daily during the entire treatment period. It is expected that the treatment period for the combination of conjugated estrogens and MPA will be for at least 28 days, preferably 30 days and preferably for long term treatment, possibly an indefinite period, as one of the primary reasons for administering combinations of conjugated estrogens and MPA is to treat or inhibit menopausal or postmenopausal disorders. It is preferred that the treatment is provided for at least 120 days, preferably 180 days, and most preferably as an indefinite treatment. Pharmaceutical packs suitably contain sufficient daily dosage units appropriate to the treatment period or in amounts which facilitate the patient’s compliance with the regimen. For example, the pharmaceutical o 30 pack may contain from 28 to 180 daily dosage units, for example from 30 to 120 daily dosage units. Pharmacaceutical packs containing large numbers of dosage units may . be further sub-packaged, for example, in 28 day periods, or 30 day periods.
Treatment periods also may vary depending on the symptoms to be treated. For example, for the treatment of vasomotor symptoms, it is preferred that the treatment may last from one month to several years, depending on the severity and duration of the symptoms. Physician evaluation along with patient interaction will assist the
; determination of the duration of treatment. For the treatment or inhibition of osteoporosis, it is preferred that the treatment period could last from six months to a _ number of years, or indefinitely.
This invention, also covers short term treatments or treatments of a finite term, that may be less than the 28 or 30 day preferred treatment period. It is anticipated that a patient may miss, or forget to take, one or a few dosages during the course of a treatment regimen, however, such patient is still considered to be receiving continuous, uninterrupted administration.
The term "fixed daily dosage" means that the same dosage amount is given every day during the treatment period. It is preferred that the MPA is given in a fixed daily dosage of about 1.5 mg, with an appropriate dose of conjugated estrogens, preferably equivalent to about 0.45 mg or about 0.30 mg PREMARIN. One aspect of this invention also covers situations in which a fixed daily dosage of the conjugated estrogens plus MPA combination is not given every day during the treatment period.
For example, the dosage of a patient may need to be adjusted (either up or down), to achieve the desired effect during the middle of a treatment period.
The term "providing," with respect to providing a dosage of one or both of the components of this invention, means either directly administering such a component of this invention, or administering a prodrug, derivative, or analog which will form the equivalent amount of the component within the body.
The daily dosage unit is preferably provided in a form for oral administration containing both the conjugated estrogens and the MPA.
The ability of the conjugated estrogens plus MPA combinations of this invention to treat or inhibit menopausal or postmenopausal disorders was confirmed in a double blind clinical study of postmenopausal women using combinations of
PREMARIN plus MPA, or placebo. In this study, patients received continuous and uninterrupted treatment for 13 cycles (1 year). The relief of vasomotor symptoms, prevention of endometrial hyperplasia, and effects on lipids, vaginal bleeding were © measured throughout the study. Additionally, the effect on bone mineral density was evaluated in patients who received continuous and uninterrupted treatment for up to : 26 cycles (2 years).
Vasomotor instability is a menopausal or postmenopausal disorder which is often manifested as hot flushes. In the clinical study described above, relief of vasomotor symptoms was analyzed in a subset of patients who experienced at least an
. average of 7-8 moderate-to-severe hot flushes per day during the 7-day period just prior to the initiation of treatment in this study. The results obtained are summarized a in the tables below. The first table shows the mean number of flushes, and the second table shows the mean daily severity of the flushes. These results are also shown in
FIGS.1and2.
Mean Number (= S.E.) of Hot Flushes Per Day
J EP ER - N
Week Placebo 0.625 P + 2.5 M* 045P+15M 03P+15M 1] 941:081 | 9502073 8.55+ 0.80 6.38 £0.72 6.98 = 0.80 6.88 + 0.74 : 8 | 7102065 | 155x061 | 149x065 | 241+060 5.36 + 0.55 0.94 + 0.53 1.13 + 0.50 *Daily dosages of P (PREMARIN) and M (MPA).
Mean Severity (+ S.E.) of Hot Flushes
EE PON SR
Week Placebo 0.625P+2.5M* 045P+1.5M 03P+1.5M 1 | 210010 | 208009 | 2.142010 | 2.07010 1.97 £0.14 1.36 + 0.13 4 [7 203:015 | 107+014 | 121x015 | 145:014 [8 | 175016 | 054+014 | 0702016 | 087014 *Daily dosages of P (PREMARIN) and M (MPA).
As shown in both tables and Figures, all dosages of PREMARIN plus MPA reduced the number and severity of hot flushes experienced by the women in this clinical study compared with women taking placebo. All differences from placebo were significant (p < 0.05) by weeks 3-4. It was unexpected, however, that the lower dosages of PREMARIN (0.45 and 0.3 mg) and MPA (1.5 mg), would rapidly reduce the number and severity of hot flushes to the same extent as the higher dose combination containing 0.625 mg PREMARIN plus 2.5 mg MPA.
Vaginal atrophy is a common menopausal or postmenopausal disorder leading to vaginal dryness, pruritus, and dyspareunia. Vaginal atrophy results from a
. sloughing of vaginal epithelial cells which, are not replaced, leading to a thinning of the vaginal lining. The effects of the lower dose conjugated estrogen plus MPA - regimens on vaginal atrophy were evaluated by comparing the vaginal maturation index of superficial cells at baseline, and after cycles 6 and 13 of treatment. The vaginal maturation index is a measure of the number of superficial vaginal epithelial cells. An increase (positive number) in the vaginal maturation index indicates a reversal (successful treatment) of vaginal atrophy. The following table summarizes the results obtained.
Vaginal Maturation Index for Superficial Cells - Median Change from Baseline [0625P+25M* [10 0} 000 10 |] [Placebo | 0 [| ~~ 0 *Daily dosages of P (PREMARIN) and M (MPA).
These data show that all the evaluated dosages of conjugated estrogens plus
MPA provided significant (p < 0.001) improvement in the vaginal maturation index versus placebo, demonstrating their ability to successfully treat or inhibit vaginal atrophy. It is notable that the lower dosages of conjugated estrogens plus MPA were as equally as effective as the 0.625 mg PREMARIN plus 2.5 mg MPA dosage in facilitating the growth of the vaginal superficial cells.
As HRT using estrogens alone has been shown to increase the relative risk of endometrial hyperplasia in postmenopausal women with a uterus, the incidence of endometrial hyperplasia was evaluated in the clinical study for patients treated with
PREMARIN plus MPA treated groups and placebo. Two independent pathologists . 25 evaluated endometrial biopsies in a blinded fashion. A patient was considered to have ‘endometrial hyperplasia if both of the primary pathologists agreed on the diagnosis. . If they disagreed, a third pathologist was consulted, and the diagnosis of hyperplasia was based on the diagnosis of the majority. The following table summarizes the results obtained after 13 cycles of treatment.
. Percent of Patients Developing Endometrial Hyperplasia
RAC FLAY EC CI
DC SN I CIN ILI
BALL a NCC RL A aC CC A * All dosages are in mg/day
These results showed that that the use of conjugated equine estrogens/MPA at a dosage of 0.625/2.5 mg/day effectively prevented the development of endometrial hyperplasia. The results also show the unexpected result that lowering the dosage of
MPA to 1.5 mg/day in PREMARIN plus MPA combinations, also continued to effectively inhibit the development of endometrial hyperplasia. The difference between the results obtained in the 1.5 mg MPA treatment groups and 2.5 mg MPA treatment groups was not statistically significant.
In providing an HRT regimen that will be acceptable to menopausal, and particularly postmenopausal women, it is highly desirable that the regimen produce a high rate of amenorrhea, as most of these women prefer a product which does not cause spotting or breakthrough bleeding. The following table shows the percent of women experiencing amenorrheic cycles at during cycles 1, 3, 6, 9, and 13.
Percent Cycles of Amenorrhea
Cycle Placebo 0625P+25M 045P+15M 03P+15M 1 For] 0 s13 J] 0 71 [0 752 00] 3 | 94 | s49 | 703 | 804 6 | 918 | 684 |] 728 | 81 9 | 936 | 708 | 805 [| 86 . 20 *Daily dosages of P (PREMARIN) and M (MPA). - The results show that greater than 90 percent of women receiving placebo were amenorrheic throughout the study. While the percent of amenorrheic women receiving daily dosages of 0.625 mg PREMARIN plus 2.5 mg MPA is satisfactory, as measured by the commercial success of PREMPRO (0.625 mg conjugated equine
. estrogens plus 2.5 mg MPA), lowering the dosages of PREMARIN to either 0.45 mg or 0.3 mg and MPA to 1.5 mg, produced an equal, if not significantly better (0.3 mg - PREMARIN plus 1.5 mg MPA) percent of women achieving amenorrhea, while still maintaining the other benefits of HRT. Additionally, as shown in the above table, and in FIG. 3, a higher percentage of amenorrhea was achieved more rapidly with the : lower dose combinations.
It is well known that the addition of progestins to ERT regimens may ameliorate some of the beneficial cardioprotective effects conferred by the estrogen, or even produce deleterious effects on the lipid levels. In this study total cholesterol (TC), HDL, HDL,, and LDL levels were measured. There was a general dose- response trend between treatment groups, that showed more favorable lipid profiles with higher doses of PREMARIN and lower doses of MPA. Patients receiving 0.625 : mg PREMARIN + 2.5 mg MPA had slight reductions in TC, significant increases in
HDL and HDL,, and significant decreases in levels of LDL. The 0.45 mg
PREMARIN plus 1.5 mg MPA dosage produced a similar favorable profile (but of less magnitude) to 0.625 mg PREMARIN + 2.5 mg MPA treated women. Women treated with 0.3 mg PREMARIN plus 1.5 mg MPA had a less favorable lipid profile (TC, HDL, HDL, and LDL), than women treated, with 0.625 mg PREMARIN plus 2.5 mg MPA, however, this profile was still better than those receiving placebo. :
During the study, adverse events were recorded and analyzed. Treatment emergent adverse events were consistent with those seen with hormone therapy. With the exception of breast pain, the side effect profile was comparable between the
PREMARIN plus MPA treatment groups. Women receiving the daily dosage of 0.3 mg PREMARIN plus 1.5 mg MPA experienced significantly less breast pain than the women taking 0.625 mg PREMARIN plus 2.5 mg MPA.
In summary the results of the clinical study demonstrated that conjugated : estrogen HRT regimens containing dosages of 1.5 mg/day of MPA were equally effective in treating menopausal or postmenopausal disorders as the regimens containing the higher dose of 2.5 mg MPA (0.625 mg PREMARIN plus 2.5 mg MPA, in particular). Higher rates of amenorrhea were also achieved more rapidly..
” td) . Additionally, less breast tenderness was observed in women taking 0.3 mg
PREMARIN plus 1.5 mg MPA, than in women taking the commercially available . : 0.625 mg PREMARIN plus 2.5 mg MPA combination.
It is well known that a rapid decrease in bone mass of both cortical (spine) and trabecular (hip) bone can be seen immediately after the menopause, with a total bone mass loss of 1% to 5% per year, continuing for 10 to 15 years. In the clinical study described above, bone mineral density (BMD) was determined using dual energy x-ray absorptiometry (DEXA) measurements of the lumbar spine (L2-L4), femoral neck, trochanter, and total body. BMD measurements were made at least twice pre- study (7-14 days apart but not to exceed 3 weeks), during cycles 6, 13, 19, and twice during cycle 26 (7-14 days apart but not to exceed 3 weeks). The final visit results (cycle 26) are summarized in the table below.
Percent BMD Change ( = S.E.) From Baseline at Final Visit * Daily dosages of P (PREMARIN) and M (MPA). + Statistically significant (p < 0.001) change from baseline. ++ Statistically significant (p = 0.004) change from baseline. # Sratistically significant (p < 0.001) difference from placebo.
The results showed that all dosages of PREMARIN plus MPA significantly increased the BMD versus baseline and placebo in the lumbar spine, femoral neck, trochanter, and total body demonstrating that combinations of conjugated estrogens » 25 plus MPA inhibited or retarded bone demineralization. These data also show that combinations of conjugated estrogens plus MPA actually increased the bone mineral - density relative to pre-study baseline levels, and also relative to patients receiving placebo.
Based on the results observed in the clinical study described above, it has been found that the continuous and uninterrupted administration of a combination a conjugated estrogens plus a dosage of about mg per of medroxyprogesterone acetate is useful in treating or inhibiting menopausal or postmenopausal disorders in perimenopausal, menopausal, or postmenopausal women (most particularly the latter).
More particularly, the combinations described herein are useful in treating or inhibiting vaginal or vulvar atrophy; atrophic vaginitis; vaginal dryness; pruritus; dyspareunia; dysuria; frequent urination; urinary incontinence; urinary tract infections; vasomotor symptoms, including hot flushes, myalgia, arthralgia, insomnia, imitability, and the like; inhibiting or retarding bone demineralization; increasing bone mineral density; and treating or inhibiting osteoporosis.
The combinations of this invention also exert a cardioprotective effect in perimenopausal, menopausal, and postmenopausal women, and are therefore useful in lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia; hyperlipidemia; cardiovascular disease; atherosclerosis; peripheral vascular disease; restenosis, and vasospasm; and inhibiting vascular wall : damage from cellular events leading toward immune mediated vascular damage.
The combinations of this invention are antioxidants, and are therefore useful : in inhibiting disorders or disease states which involve free radicals. More particularly, the combinations of this invention are useful in treating or inhibiting free radical involvement in the development of cancers, central nervous system disorders,
Alzheimer's disease, bone disease, aging, inflammatory disorders, peripheral vascular disease, rheumatoid arthritis, autoimmune diseases, respiratory distress, emphysema, prevention of reperfusion injury, viral hepatitis, chronic active hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral sclerosis, aging effects, adult respiratory distress syndrome, central nervous system trauma and stroke, or . injury during reperfusion procedures.
The combinations of this invention are useful in treating or inhibiting " dementias, neurodegenerative disorders, and Alzheimer's disease; providing neuroprotection or cognition enhancement.
C. The conjugated estrogens and medroxyprogesterone acetate described in this invention can be either formulated as separate tablets or as a unitary combination . tablet. a
Either of the components or the combination may be formulated neat or may be combined with one or more pharmaceutically acceptable carriers for administration. For example, solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard- filled or liquid-filled capsules. Oral administration of the compounds is preferred.
Conjugated estrogens and MPA can be formulated in a number of ways to provide a single combination dosage form. Conjugated estrogens can be incorporated within the core of a compressed tablet and the progestin can be placed in an overcoating consisting of a compressed, film or sugar coat, as described in U.S.
Patent 5,547,948, which is hereby incorporated by reference. The tablets described in
U.S. Patent 5,547,948 are suitable for formulation of the conjugated estrogens and
MPA described in this invention as a unitary tablet. U.S. Patent 5,908,638, which is : hereby incorporated by reference, also describes combination tablets which are suitable for formulation of the conjugated estrogens and MPA described in this invention as a unitary tablet. 3 Conjugated estrogens may be formulated in a core containing the conjugated estrogens, and several components including alcohol, hydroxypropyl methyl . cellulose, lactose. monohydrate, magnesium stearate, and starch. The core can be covered with a coating made from components such as ethylcellulose, and triethyl citrate.
w Both components can be incorporated in the compressed tablet core or in a tablet coating formulated to maintain drug stability and provide adequate oral , bioavailability. For example, the progestin can be micronized.
Conjugated estrogens can be incorporated in granules, spheroids or other multiparticulate forms, and, if necessary, coated to provide adequate stability. These multiparticulates can be combined, in the appropriate proportions, with a powder blend, granulation or multiparticulates containing the progestin and incorporated into hard gelatin capsules.
This invention also provides a pharmaceutical does pack, containing any number of daily pharmaceutical dosage units. Preferably, and conventionally, the pack contains 28 tablets or multiples thereof. The pack should indicate that the dosage units are to be taken consecutively on a daily basis until the treatment period has ended, or until the pack has been completed. The next pack should be started on the next consecutive day. For combinations containing a unitary dosage tablet
Co 15 containing both conjugated estrogens and MPA, it is preferable that the pack contain one tablet corresponding to each day of administration. For combinations containing separate dosage units of conjugated estrogens and MPA, it is preferable that each one tablet of each correspond to each given day's administration, as indicated on the pill : pack.
Claims (61)
- " CLAIMS. 1. Use of conjugated estrogens and medroxyprogesterone acetate in the manufacture of pharmaceutical packs comprising daily dosage units for the treatment or inhibition of menopausal or postmenopausal disorders in a perimenopausal, menopausal, or postmenopausal woman in need thereof, wherein each daily dosage unit comprises a combination of conjugated estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate.
- 2. The use according to claim 1 which.comprises treating or inhibiting vasomotor symptoms in a perimenopausal, menopausal, or postmenopausal woman in need thereof.
- 3. The use according to claim 2, wherein the vasomotor symptom is hot flushes.
- 4. The use according to claim 1 which comprises inhibiting or retarding bone demineralization or treating or inhibiting osteoporosis in a perimenopausal, menopausal, or postmenopausal woman in need thereof. g 20
- S. The use according to claim 1 which comprises treating or inhibiting vaginal or vulvar atrophy; atrophic vaginitis; vaginal dryness; pruritus; dyspareunia; dysuria; frequent urination; urinary incontinence; urinary tract infections in a perimenopausal, menopausal, or postmenopausal woman in need thereof.
- 6. The use according to claim 1 which comprises lowering cholesterol, triglycerides, Lp(a), or LDL levels; inhibiting or treating hypercholesteremia; hyperlipidemia; cardiovascular disease; atherosclerosis; peripheral vascular disease; restenosis, vasospasm; or inhibiting vascular wall damage from cellular events leading toward immune mediated vascular damage, in a perimenopausal, menopausal, Y 30 or postmenopausal woman in need thereof.y
- 7. Use of conjugated estrogens and medroxyprogesterone acetate in the manufacture of pharmaceutical packs comprising daily dosage units for treating or inhibiting free radical involvement in the development of cancers, central nervous system disorders, Alzheimer's disease, bone disease, aging, inflammatory disorders, peripheral vascular disease, rheumatoid arthritis, autoimmune diseases, respiratory@ distress, emphysema, prevention of reperfusion injury, viral hepatitis, chronic active hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral “ sclerosis, aging effects, adult respiratory distress syndrome, central nervous system trauma and stroke, or injury during reperfusion procedures in a perimenopausal, menopausal, or postmenopausal woman in need thereof, wherein each daily dosage unit comprises a combination of conjugated estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate.
- 8. Use of conjugated estrogens and medroxyprogesterone acetate in the manufacture of pharmaceutical packs comprising daily dosage units for treating or inhibiting dementias, neurodegenerative disorders, and Alzheimer's disease; providing neuroprotection or cognition enhancement in a perimenopausal, menopausal, or postmenopausal woman in need thereof, wherein each daily dosage unit comprises a : combination of conjugated estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate.
- 9. Use of conjugated estrogens and medroxyprogesterone acetate in the manufacture of pharmaceutical packs comprising daily dosage units for increasing bone mineral density in a perimenopausal, menopausal, or postmenopausal woman in need thereof, wherein each daily dosage unit comprises a combination of conjugated estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate.
- 10. Use of conjugated estrogens and medroxyprogesterone acetate in the manufacture of pharmaceutical packs comprising daily dosage units of minimizing or reducing levels of breast pain in a woman receiving hormone replacement therapy, wherein each daily dosage unit comprises a combination of conjugated estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate.
- 11. Use of conjugated estrogens and medroxyprogesterone acetate in the . 30 manufacture of pharmaceutical packs comprising daily dosage units for minimizing spotting or breakthrough bleeding, or achieving amenorrhea in a woman receiving N hormone replacement therapy, wherein each daily dosage unit comprises a combination of conjugated estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate.
- 12. The use according to claim 11, wherein the time for minimizing spotting or breakthrough bleeding or achieving the onset of amenorrhea is hastened.
- 13. The use according to any of claims 1 to 12, wherein the conjugated estrogens ~~ 5 is synthetic conjugated estrogens, A.
- 14. The use according to any of claims 1 to 12, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 15. The use according to any of the preceding claims, wherein the daily dosage of conjugated estrogens is between about 0.625 mg and about 0.3 mg.
- 16. The use according to any of the preceding claims, wherein the daily dosage of conjugated estrogens, is between about 0.45 mg and about 0.3 mg.
- 17. The use according to any of the preceding claims wherein the daily dosage of conjugated estrogens is about 0.45 mg.
- 18. The use according to any preceding claim wherein the daily dosage of conjugated estrogens, is about 0.3 mg.
- 19. The use according to any of the preceding claims wherein the pharmaceutical pack contains fixed daily dosage units.
- 20. The use according to any of the preceding claims in which the pharmaceutical pack contains at least 28 daily dosage units.
- 21. The use according to any preceding claim in which the pharmaceutical pack comprises up to 180 daily dosage units.
- 22. The use according to any of the preceding claims in which the pharmaceutical w pack contains at least 30 daily dosage units.
- 23. The use according to any preceding claim in which the pharmaceutical pack comprises up to 120 daily dosage units.
- » 24. The use according to any preceding claim in which the medroxyprogesterone acetate is micronized.
- 25. The use according to any preceding claim in which the daily dosage unit is provided once a day.
- 26. The use according to any preceding claim in which the daily dosage unit is provided for oral administration.
- 27. The use according to any preceding claim in which the daily dosage unit contains 0.45 mg of conjugated equine estrogens and 1.5 mg of medroxyprogesterone acetate.
- 28. The use according to any preceding claim in which the daily dosage unit contains 0.3 mg of conjugated equine estrogens and 1.5 mg of medroxyprogesterone acetate. :
- 29. A pharmaceutical composition for use in treating menopausal or postmenopausal disorders in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises conjugated estrogens, a dosage of about 1.5 mg medroxyprogesterone acetate, and a pharmaceutical carrier.
- 30. A pharmaceutical dosage unit which comprises conjugated estrogens, a dosage of about 1.5 mg of medroxyprogesterone acetate, and a pharmaceutical carrier.
- 31. A pharmaceutical pack comprising daily dosage units comprising a combination of conjugated estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate
- . 30 32. The composition, unit or pack according to claim 29 or 30 or 31, wherein the conjugated estrogens is conjugated equine estrogens, USP.
- 33. The composition, unit or pack according to claim 29 or 30 or 31, wherein the conjugated estrogens is synthetic conjugated estrogens, A.) PCT/US01/40302 oo 22 oo
- 34, The composition, unit or pack according to claim 32 or 33, wherein the dosage is between about 0.45 mg and about 0.30 mg. oo Co
- 35. The composition, unit or pack according to claim 32 or 33 wherein the CC dosage is about 0.45 mg or 0.30 mg. :
- 36. The composition, unit or pack according to claim 29 or 30 or 31, wherein . . the medroxyprogesterone acetate is micronized. oC : :
- 37. The pharmaceutical pack according to claim 31 which comprises up to. 180 fixed daily dosage units.
- 38. The pharmaceutical pack according to claim 37 containing at least 28 fixed daily dosage units. Co
- 39. The pharmaceutical pack according to claim 37 containing at least 30 fixed daily dosage units.
- 40. A method of inhibiting menopausal or postmenopausal disorders in a , perimenopausal, menopausal, or postmenopausal woman, which comprises providing to said woman continuously and uninterruptedly over the administration period, a combination of conjugated estrogens and a daily dosage. of about 1.5 mg of medroxyprogesterone acetate.
- 41. A method according to claim 40 which comprises inhibiting vasomotor symptoms in a perimenopausal, menopausal, or postmenopausal woman. oC :
- 42. The method according to claim 41, wherein the vasomotor symptom is ~ hot flushes. - AMENDED SHEETPCT/US01/40302 : } ©
- 43. A method according to claim 40 which comprises inhibiting or retarding bone demineralization, Or inhibiting osteoporosis in a perimenopausal, menopausal, or postmenopausal woman. oo :
- 44. A method according to claim 40 which comprises inhibiting vaginal or vulvar atrophy; atrophic vaginitis; vaginal dryness; pruritus; dyspareunia; dysuria; frequent urination; urinary incontinence; urinary tract infections in fo ~ a perimenopausal, menopausal, or postmenopausal ‘woman.
- 45. A method according to claim 40 which comprises lowering cholesterol, triglycerides, Lp(a), or LDL levels; inhibiting hypercholesteremia; - hyperlipidemia; cardiovascular disease; atherosclerosis; peripheral vascular disease; restenosis, vasospasm; Of inhibiting vascular wall damage from © cellular events leading toward immune mediated vascular damage, in a - perimenopausal, menopausal, or postmenopausal ‘woman. . 20
- 46. A method of inhibiting free radical involvement in the development of oo cancers, central nervous system disorders, Alzheimer’s disease, bone disease, ] aging, inflammatory disorders, peripheral vascular disease, rheumatoid arthritis, . "autoimmune diseases, respiratory distress, emphysema, prevention of reperfusion injury, viral hepatitis, chronic active hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral sclerosis, aging effects, adult respiratory distress syndrome, central nervous system trauma and stroke, or injury during reperfusion procedures in a perimenopausal, menopausal, or postmenopausal woman which comprises providing to said woman continuously and uninterruptedly over the administration period, a combination of conjugated y 30 estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate. :
- 47. A method of inhibiting dementias, neurodegenerative disorders, and 5 Alzheimer’s disease; providing neuroprotection or cognition enhancement in a perimenopausal, menopausal, or postmenopausal woman, which comprises AMENDED SHEETPCT/US01/40302 i -24- providing to said woman continuously and uninterruptedly over the administration period, a combination of conjugated estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate. no Co
- 48. © A method of increasing bone mineral density in a perimenopausal, menopausal, or postmenopausal woman, which comprises providing to said - woman continuously and uninterruptedly over the administration period, a combination of conjugated estrogens and a daily dosage of about 1.5 mg of : medroxyprogesterone acetate. oo
- 49. A method of minimizing or reducing levels of breast pain in a woman © 15 receiving hormone replacement therapy, which comprises providing to said woman continuously and uninterruptedly over the administration period, a C combination of conjugated estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate. : . oo 20
- 50. A method of minimizing spotting or breakthrough bleeding; or achieving : amenorrhea in a woman receiving hormone replacement therapy, which - comprises providing to said woman continuously and uninterruptedly over the , administration period, a combination of conjugated estrogens and a daily dosage of about 1.5 mg of medroxyprogesterone acetate. . - 25 - ) . s
- 51. The method according to claim 50, wherein the time for minimizing spotting or breakthrough bleeding or achieving the onset of amenorrhea is ] hastened.
- 52. The method according to any of claims 40 to 51, wherein the conjugated estrogens is synthetic conjugated estrogens, A. :
- 53. The method according to any of claims 40 to 51, wherein the conjugated estrogens is conjugated equine estrogens, USP. AMENDED SHEETPCT/US01/40302
- 54. The method according to any of claims 40 to 51, wherein the daily N dosage of conjugated estrogens is between about 0.625 mg and about 0.3 mg.
- 55. The method according to any of claims 40 to 53, wherein the daily - dosage of conjugated estrogens, is between about 0.45 mg and about 0.3 mg.
- 56. The method according to any of claims 40 to 53 wherein the daily dosage of conjugated estrogens, is about 0.45 mg or about 0.3 mg.
- 57. The method according to any of claims 40 to 53 in which the daily ~ dosage unit contains 0.45 mg of conjugated equine estrogens and 1.5 mg of medroxyprogesterone acetate. :
- 58. The method according to any of claims 40 to 53 in which the daily dosage unit contains 0.30 mg of conjugated equine estrogens and 1.5 mg of medroxyprogesterone acetate. :
- 59. A substance or composition for use in a method of treating or inhibiting menopausal or postmenopausal disorders in a perimenopausal, menopausal, or . postmenopausal woman, said substance or composition comprising a combination © of conjugated estrogens and a daily dosage of about 1.5 mg of : 25 medroxyprogesterone acetate, and said method comprising providing said: . substance or composition to said woman continuously and uninterruptedly over the treatment period.
- 60. A substance or composition for use in a method of treatment according) . 30 to claim 59 which comprises treating or inhibiting vasomotor symptoms in a perimenopausal, menopausal, or postmenopausal woman in need thereof.
- 61. A substance or composition for use in a method of treatment according to claim 60, wherein the vasomotor symptom is hot flushes. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19063000P | 2000-03-20 | 2000-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200208369B true ZA200208369B (en) | 2004-01-26 |
Family
ID=32592628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200208369A ZA200208369B (en) | 2000-03-20 | 2002-10-17 | Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate. |
Country Status (2)
Country | Link |
---|---|
UA (1) | UA79071C2 (en) |
ZA (1) | ZA200208369B (en) |
-
2001
- 2001-03-16 UA UA2002108296A patent/UA79071C2/en unknown
-
2002
- 2002-10-17 ZA ZA200208369A patent/ZA200208369B/en unknown
Also Published As
Publication number | Publication date |
---|---|
UA79071C2 (en) | 2007-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001250034B2 (en) | Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate | |
AU2001250034A1 (en) | Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate | |
AU2002336245B2 (en) | Hormone replacement therapy | |
AU2002336245A1 (en) | Hormone replacement therapy | |
AU2002338277A1 (en) | Estrogen replacement therapy | |
EP1368037A2 (en) | Estrogen replacement therapy | |
US20030216367A1 (en) | Hormone replacement therapy | |
US20030216368A1 (en) | Hormone replacement therapy | |
US20030191103A1 (en) | Hormone replacement therapy | |
US20030191097A1 (en) | Hormone replacement therapy | |
US20030207850A1 (en) | Hormone replacement therapy | |
ZA200208369B (en) | Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate. | |
EP1857110A2 (en) | Hormone replacement therapy |